120
Participants
Start Date
February 28, 2025
Primary Completion Date
December 31, 2026
Study Completion Date
February 28, 2027
Relugolix
"* Relugolix (40 mg) tablet administered orally once daily;~* megestrol acetate (1 mg) administered orally once daily;~* medroxyprogesterone acetate (2 mg) administered orally once daily"
Relugolix placebo
"Relugolix (0 mg) tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.~megestrol acetate (0 mg) administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.~medroxyprogesterone acetate (0 mg) administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor."
RECRUITING
Peking Union Medical College Hospital, Beijing
Qilu Pharmaceutical Co., Ltd.
INDUSTRY